Author: George Underwood

The oral therapy is the first and only Janus kinase (JAK) inhibitor approved in the US for this patient population

Drug is the first Fc-free, PEGylated anti-TNF treatment option for this indication and marks UCB’s entry into immuno-dermatology

Firm says re-examination procedure “would not be the most appropriate format” to address all concerns raised by the CHMP

Drug fails to show any benefit over Tecentriq alone in lung cancer.

Partnership between Health Innovation Manchester, the Greater Manchester Health and Social Care Partnership, and the Dementia Industry Group will focus on finding the best care and treatment options